{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:44:13Z","timestamp":1785879853363,"version":"3.56.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:56:06Z","timestamp":1760799366000},"page":"S73-S80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["Updates of spinal muscular atrophy in advanced therapies"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-9138","authenticated-orcid":false,"given":"Wen-Chin","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Tso","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-6951","authenticated-orcid":false,"given":"Li-Kai","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jfma.2025.10.018_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genet Med : Off J Am College Med Gen"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017067","article-title":"Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study","volume":"6","author":"Su","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","article-title":"Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene","volume":"125","author":"Al\u00edas","year":"2009","journal-title":"Hum Genet"},{"issue":"11","key":"10.1016\/j.jfma.2025.10.018_bib8","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord : NMD"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord : NMD"},{"issue":"14","key":"10.1016\/j.jfma.2025.10.018_bib11","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"16","key":"10.1016\/j.jfma.2025.10.018_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22169029","article-title":"The importance of digging into the genetics of SMN genes in the therapeutic scenario of spinal muscular atrophy","volume":"22","author":"Costa-Roger","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.jfma.2025.10.018_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011210","article-title":"In search of spinal muscular atrophy disease modifiers","volume":"25","author":"Chudakova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfma.2025.10.018_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1242828","article-title":"NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy","volume":"17","author":"El Khoury","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00439-012-1171-5","article-title":"Mouse models of SMA: tools for disease characterization and therapeutic development","volume":"131","author":"Bebee","year":"2012","journal-title":"Hum Genet"},{"key":"10.1016\/j.jfma.2025.10.018_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ejhg.2012.222","article-title":"Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585","volume":"21","author":"Schreml","year":"2013","journal-title":"Eur J Hum Genet : EJHG (Eur J Hum Genet)"},{"issue":"18","key":"10.1016\/j.jfma.2025.10.018_bib20","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jfma.2025.10.018_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.018_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.018_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.10.018_bib25","article-title":"Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study","volume":"39","author":"G\u00fcnther","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jfma.2025.10.018_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115230","article-title":"Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy","volume":"389","author":"Hsieh","year":"2025","journal-title":"Exp Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2025.10.018_bib28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord : NMD"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-Year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acn3.51562","article-title":"Scientific rationale for a higher dose of nusinersen","volume":"9","author":"Finkel","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"15_supplement","key":"10.1016\/j.jfma.2025.10.018_bib31","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","article-title":"Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study (1640)","volume":"94","author":"Castro","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.018_bib32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal Muscular Atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.018_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JND-221667","article-title":"DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part A results","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.018_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.018_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.018_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib39","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.018_bib42","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib43","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/brain\/awac125","article-title":"Pre-symptomatic spinal muscular atrophy: a proposed nosology","volume":"145","author":"Finkel","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.jfma.2025.10.018_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene Abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"issue":"17\u201318","key":"10.1016\/j.jfma.2025.10.018_bib48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210268","article-title":"Safety and efficacy of IV onasemnogene abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b SMART study","volume":"104","author":"McMillan","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose Study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"15","key":"10.1016\/j.jfma.2025.10.018_bib51","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a selective survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.018_bib53","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2025.10.018_bib55","first-page":"1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib56","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib58","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1111\/bcp.15319","article-title":"Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam","volume":"88","author":"Kletzl","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH Study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.018_bib60","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib61","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s11010-024-05120-y","article-title":"Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions","volume":"480","author":"Wetzlich","year":"2025","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib62","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00018-022-04408-w","article-title":"Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases","volume":"79","author":"Abati","year":"2022","journal-title":"Cell Mol Life Sci : CMLS"},{"issue":"19","key":"10.1016\/j.jfma.2025.10.018_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910273","article-title":"Taldefgrobep alfa and the phase 3 RESILIENT trial in spinal muscular atrophy","volume":"25","author":"Servais","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.jfma.2025.10.018_bib64","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1074\/jbc.RA119.012293","article-title":"Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015","volume":"295","author":"Dagbay","year":"2020","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.018_bib65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(25)00225-X","article-title":"Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"24","author":"Crawford","year":"2025","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac324","article-title":"Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4","volume":"5","author":"Stam","year":"2023","journal-title":"Brain Commun"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00431-025-06184-8","article-title":"Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safety","volume":"184","author":"Xing","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"739","key":"10.1016\/j.jfma.2025.10.018_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk9109","article-title":"The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis","volume":"16","author":"Skov","year":"2024","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib69","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-Year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib70","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","article-title":"Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention","volume":"22","author":"Tizzano","year":"2018","journal-title":"Eur J Paediatr Neurol : EJPN : official journal of the European Paediatric Neurology Society"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib71","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/22143602241288095","article-title":"Newborn screening programs for spinal muscular atrophy worldwide in 2023","volume":"11","author":"Vr\u0161\u010daj","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/dmcn.15314","article-title":"The cost-effectiveness of newborn screening for spinal muscular atrophy","volume":"65","author":"Landfeldt","year":"2023","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.018_bib73","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","article-title":"Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening","volume":"181","author":"Pane","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.018_bib74","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213799","article-title":"Gestational age at birth and clinical manifestations of spinal muscular atrophy","volume":"105","author":"Farrar","year":"2025","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jfma.2025.10.018_bib75","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for prenatal therapy of spinal muscular atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib76","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.26357","article-title":"Reply to: the 4-Copy conundrum in the treatment of infants with spinal muscular atrophy","volume":"91","author":"Yeo","year":"2022","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.018_bib77","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ana.26358","article-title":"The 4-Copy conundrum in the treatment of infants with spinal muscular atrophy","volume":"91","author":"Deng","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jfma.2025.10.018_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark Insights"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.018_bib79","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","article-title":"Biomarkers in 5q-associated spinal muscular Atrophy\u2014a narrative review","volume":"270","author":"Lapp","year":"2023","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.018_bib80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00415-025-13314-7","article-title":"Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time","volume":"272","author":"Corti","year":"2025","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.018_bib81","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.018_bib82","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.018_bib83","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul Disord : NMD"},{"key":"10.1016\/j.jfma.2025.10.018_bib84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejpn.2023.11.006","article-title":"The emerging spectrum of neurodevelopmental comorbidities in early-onset spinal muscular Atrophy","volume":"48","author":"Baranello","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jfma.2025.10.018_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2024.05.002","article-title":"Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life","volume":"51","author":"Steffens","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.018_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12484-8","article-title":"Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy","volume":"15","author":"Buchignani","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.nmd.2022.06.005","article-title":"264th ENMC international Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th - 21st 2021","volume":"32","author":"Detering","year":"2022","journal-title":"Neuromuscul Disord : NMD"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.018_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13051336","article-title":"Low bone mass in ambulatory spinal muscular atrophy: a proactive approach for an often-overlooked impairment","volume":"13","author":"Trancho","year":"2024","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib89","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s10072-025-08155-1","article-title":"Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review","volume":"46","author":"Gnazzo","year":"2025","journal-title":"Neurol Sci : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.018_bib90","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.018_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord NMD"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:47:33Z","timestamp":1785876453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625005625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":91,"alternative-id":["S0929664625005625"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates of spinal muscular atrophy in advanced therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}